Successful treatment of secukinumab in severe plaque psoriasis
A case report
Keywords:
biologic agents, human, disease, psoriasis, secukinumabAbstract
Psoriasis is a persistent, chronic condition that manifests on the skin, joints, and other visible places that compromises the quality of life. The vast understanding of the pathophysiology of psoriasis has led to a rise in the use of biological therapy in treating psoriasis in recent years. A 48-year-old woman with severe plaque psoriasis was previously treated with methotrexate and phototherapy for 3 months, however, the treatment showed no significant improvement. The patient was then treated with a biological agent, namely secukinumab, with a dose of 150 mg weekly for 5 weeks followed by one dose a month later. The symptoms were improved considerably after 10 weeks of observation, which indicated by the decrease in Psoriasis Area Severity Index (PASI) score and the Dermatology Life Quality Index (DLQI) score. There was no significant side effect during the observation. This case showed that secukinumab therapy at a dose of 150 mg can successfully treat severe plaque psoriasis patient.
Downloads
References
Augustin, M., Jullien, D., Martin, A., Peralta, C. (2020). Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. Journal of the European Academy of Dermatology and Venereology, 34(6), 11741185. https://doi.org/10.1111/jdv.16180
Gerdes, S., Pinter, A., Papavassilis, C., & Reinhardt, M. (2020). Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 34(3), 533–541. https://doi.org/10.1111/jdv.16004
Gudjonsson. J. E., & Elder, J. T. (2019). Psoriasis. In Kang, S., Amagai, M., D, Bruckner, A. L., MD, Enk, A. H., Margolis, D. J., McMichael, A. J., Orringer, J. S (Eds.). Fitzpatrick Dermatology. (9th ed., Vol. 1, pp. 457497). McGraw-Hill Education.
Kofoed, K., Skov, L., & Zachariae, C. (2015). New drugs and treatment targets in psoriasis. Acta dermato-venereologica, 95(2), 133–139. https://doi.org/10.2340/00015555-1931
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T. F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., Papavassilis, C., FIXTURE Study Group. (2014). Secukinumab in plaque psoriasis--results of two phase 3 trials. The New England journal of medicine, 371(4), 326–338. https://doi.org/10.1056/NEJMoa1314258
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., Richards, H., Pricop, L., Ligozio, G., Patekar, M., Mpofu, S., & FUTURE 2 Study Group. (2015). Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 386(9999), 1137–1146. https://doi.org/10.1016/S0140-6736(15)61134-5
Meneguin, S., de Godoy, N.A., Pollo, C. F., Miot, H. A., de Oliveira, C. (2020). Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatology, 20(22). https://doi.org/10.1186/s12895-020-00116-9
Nast, A., Spuls, P. I., van der Kraaij, G., Gisondi, P., Paul, C., Ormerod, A. D., Saiag, P., Smith, C. H., Dauden, E., de Jong, E. M., Feist, E., Jobling, R., Maccarone, M., Mrowietz, U., Papp, K. A., Reich, K., Rosumeck, S., Talme, T., Thio, H. B., van de Kerkhof, P., Werner, R. N., Dressler, C. (2017). European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology: JEADV, 31(12), 1951–1963. https://doi.org/10.1111/jdv.14454
Novianto, E., Budianti, W. K., Fitri, E. M., Wiryadi, B. E., Soebaryo, R. W., Pusponegoro, E. H. D., Effendi, E. H., Rahmayunita, G., Irawan, A., Prakoeswa, C. R. S., Kariosentono, H, Roesyanto, I. D., Adiguna, M. S., Adji, A., Rofiq, A., Nopriyati, Anum, Q., Sugianto, Y. F. R., Djohan, Radiono, S., Triwahyudi, D., Anindya, S., Debinta, A. A., Effendy, I. (2021). Indonesian clinical practice guidelines for systemic and biologic agents for adults with plaque psoriasis. Journal of General Procedural Dermatology Venereology Indonesia, 5(3);152170. http://dx.doi.org/10.19100/jdvi.v5i3.244
Prakoeswa, C. R. S., Hidayati, A. N., Hendaria, M. P., Listiawan, M. Y., Utomo, B., Damayanti, Citrashanty, I., Anggraeni, S., Umborowati, M. A., & Ervianti, E. (2021). The Profile of Psoriasis Vulgaris Patients: A Descriptive Study. Berkala Ilmu Kesehatan Kulit Dan Kelamin, 33(3), 173–181. https://doi.org/10.20473/bikk.V33.3.2021.173-181
Rizqia, U., Kurniawan, R., Fitri., E. W. (2020). Profil Penderita Psoriasis di Poli Kulit dan Kelamin RSUD Meuraxa kota Banda Aceh periode tahun 2016-2019. Jurnal Medika Malahayati, 4(4), 268–273. https://doi.org/10.33024/jmm.v4i4.3396
Rønholt, K., & Iversen, L. (2017). Old and New Biological Therapies for Psoriasis. International journal of molecular sciences, 18(11), 2297. https://doi.org/10.3390/ijms18112297
Shirley, M., & Scott, L. J. (2016). Secukinumab: A Review in Psoriatic Arthritis. Drugs, 76(11), 1135–1145. https://doi.org/10.1007/s40265-016-0602-3
Siswati, A. S., Prakoeswa, C. R. S., Triwahyudi, D., Budianti, W. K., Mawardi, P., Dwiyana, R. V., Widaty, S., Hindritiani, R., Diba, S., Yogianti, F., Pangastuti, M. (2021). Panduan Praktis Klinis Bagi Dokter Spesialis Dermatologi dan Venereologi Indonesia. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia.
Thaçi, D., Körber, A., von Kiedrowski, R., Bachhuber, T., Melzer, N., Kasparek, T., Duetting, E., Kraehn-Senftleben, G., Amon, U. and Augustin, M. (2020), Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. Journal of the European Academy of Dermatology and Venereology, 34, 310318. https://doi.org/10.1111/jdv.15962
Weige, N., & McBane, S. (2013). Psoriasis. Am Fam Physician, 87(9):626633.
Yunita, I., & Anggraeni, S. (2022). Secukinumab Therapy in Psoriasis Management. Berkala Ilmu Kesehatan Kulit Dan Kelamin, 34(1), 59–65. https://doi.org/10.20473/bikk.V34.1.2022.59-65
Zhong, H., Yang, H., Mao, Z., Chai, X., Li, S. (2021). Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcomes, 19(271). https://doi.org/10.1186/s12955-021-01902-w
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
